{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:25:34Z","timestamp":1788279934458,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.clinre.2023.102111","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T06:33:19Z","timestamp":1678861999000},"page":"102111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"47","author":[{"given":"Ishaque","family":"Hameed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1845-8952","authenticated-orcid":false,"given":"Javeria","family":"Hayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Marsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Abdus","family":"Samad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafay","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer Mustafa","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Omer","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanza","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaneez","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Krasuski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2023.102111_bib0001","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.cld.2015.10.011","article-title":"Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children","volume":"20","author":"Kleiner","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.clinre.2023.102111_bib0002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2023.102111_bib0003","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2337\/dc10-2229","article-title":"Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes study","volume":"34","author":"Williamson","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinre.2023.102111_bib0004","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1053\/j.gastro.2011.06.061","article-title":"Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States","volume":"141","author":"Charlton","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2023.102111_bib0005","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2023.102111_bib0006","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clinre.2023.102111_bib0007","unstructured":"National Institute for Health and Care Excellence (UK) Non-alcoholic fatty liver disease: assessment and management, http:\/\/www.niceorg.uk\/guidance\/ng49; 2021 [accessed 13 December 2021]"},{"key":"10.1016\/j.clinre.2023.102111_bib0008","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2023.102111_bib0009","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.2337\/dc07-0141","article-title":"Thiazolidinediones and heart failure: a teleo-analysis","volume":"30","author":"Singh","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinre.2023.102111_bib0010","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinre.2023.102111_bib0011","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.clinre.2023.102111_bib0012","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinre.2023.102111_bib0013","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2011"},{"key":"10.1016\/j.clinre.2023.102111_bib0014","unstructured":"Higgins J.P.T., Green S. Imputing standard deviations for changes from baseline, Cochrane handbook for systematic reviews of interventions,http:\/\/handbook-5-1.cochrane.org\/chapter_16\/16_1_3_2_imputing_standard_deviations_for_changes_from_baseline.htm; 2021 [accessed 06 November 2021]"},{"key":"10.1016\/j.clinre.2023.102111_bib0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta\u2013analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clinre.2023.102111_bib0016","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clinre.2023.102111_bib0017","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.clinre.2023.102111_bib0018","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/jdi.13457","article-title":"Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone","volume":"12","author":"Cho","year":"2021","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.clinre.2023.102111_bib0019","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clinre.2023.102111_bib0020","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-Week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinre.2023.102111_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.clinre.2023.102111_bib0022","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6470137","article-title":"Effect of tofogliflozin on body composition and glycemic control in japanese subjects with type 2 diabetes mellitus","volume":"2018","author":"Kamei","year":"2018","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.clinre.2023.102111_bib0023","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/14656566.2017.1317748","article-title":"The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial","volume":"18","author":"Kato","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinre.2023.102111_bib0024","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3346\/jkms.2012.27.2.184","article-title":"Comparison of visceral fat and liver fat as risk factors of metabolic syndrome","volume":"27","author":"Lee","year":"2012","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.clinre.2023.102111_bib0025","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/gut.2009.205088","article-title":"Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years","volume":"59","author":"Wong","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.clinre.2023.102111_bib0026","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2023.102111_bib0027","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2023.102111_bib0028","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2023.102111_bib0029","first-page":"e3","article-title":"Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects","volume":"1","author":"Napolitano","year":"2013","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.clinre.2023.102111_bib0030","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diacare.25.3.517","article-title":"Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes","volume":"25","author":"Miyazaki","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinre.2023.102111_bib0031","series-title":"Lipid management in adults","year":"2009"},{"key":"10.1016\/j.clinre.2023.102111_bib0032","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2147\/DMSO.S184767","article-title":"Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis","volume":"11","author":"Seko","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.clinre.2023.102111_bib0033","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinre.2023.102111_bib0034","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","article-title":"Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials","volume":"370","author":"Lago","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2023.102111_bib0035","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT03646292, comparison of the effects of thiazolidinediones (TZD), Sodium- Glucose Cotransporter 2 inhibitors(sglt2i) alone and tzd \/SGLT2i combination therapy on non-alcoholic fatty liver disease in type 2 diabetic patients with fatty liver; 2018 August 24; [about 8 screens],https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03646292?cond=thiazolidinedione%2C+SGLT2+inhibitor&draw=2&rank=2; 2022 [accessed 18 March 2022]."},{"key":"10.1016\/j.clinre.2023.102111_bib0036","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/cells9010037","article-title":"Anti-NASH drug development hitches a lift on PPAR agonism","volume":"9","author":"Boeckmans","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.clinre.2023.102111_bib0037","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials","volume":"68","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2023.102111_bib0038","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jhep.2019.09.018","article-title":"Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis","volume":"72","author":"Bril","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2023.102111_bib0039","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111S","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.clinre.2023.102111_bib0040","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","article-title":"Renal Na(+)-glucose cotransporters","volume":"280","author":"Wright","year":"2001","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740123000360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740123000360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:34:28Z","timestamp":1761896068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740123000360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2210740123000360"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2023.102111","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2023.102111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102111"}}